Core Viewpoint - The implementation plan for the high-quality development of the traditional Chinese medicine (TCM) industry from 2026 to 2030 aims to establish a collaborative development system for the entire TCM industry chain by 2030 [1] Group 1: Quality Improvement - The plan emphasizes the importance of improving the quality of raw materials by establishing high-standard production bases in major production areas [2] - Factors such as origin, climate, soil, and cultivation techniques significantly affect the quality of medicinal materials, which in turn impacts the therapeutic effects of TCM [2] - As of June 2025, China has supported artificial breeding of 14 endangered medicinal materials and has achieved industrial production of substitutes for rare materials [2] Group 2: Innovation and Collaboration - The plan proposes collaborative innovation initiatives to enhance the transformation of TCM preparations in medical institutions, focusing on overcoming technological bottlenecks [3] - A cooperative model involving renowned doctors, hospitals, schools, and enterprises is encouraged to integrate resources effectively [3] - The Beijing Daxing District's Guang'anmen Hospital has successfully transformed over 20 TCM varieties, with 4 of them becoming innovative TCM drugs [3] Group 3: Digital Transformation - The plan outlines actions to enhance manufacturing capabilities, including the establishment of 20 smart factories and the cultivation of 10 green factories [4] - The application of smart devices in the TCM industry is expected to facilitate the transition from traditional experience-based practices to precision-based methods [4] - The use of artificial intelligence and big data is aimed at constructing knowledge graphs for classic formulas and experiences from renowned TCM practitioners [4] Group 4: Future Outlook - The next five years are deemed critical for the transformation and upgrading of the TCM industry, with expectations for further modernization and high-quality development as the plan's measures are implemented [5]

Core Viewpoint - The implementation plan for the high-quality development of the traditional Chinese medicine (TCM) industry has been jointly issued by eight departments, aiming to establish a collaborative development system for the entire TCM industry chain by 2030 [1]. Group 1: Quality Improvement of Raw Materials - The plan emphasizes the importance of improving the quality of raw materials, proposing the establishment of high-standard production bases for TCM raw materials in major production areas [2]. - Factors such as origin, climate, soil, and cultivation techniques significantly influence the quality of medicinal materials, which directly affects the therapeutic effects of TCM [2]. - As of June 2025, China has supported the artificial breeding of 14 endangered medicinal materials, with over 300 out of 600 commonly used TCM materials already achieving artificial cultivation [2]. Group 2: Innovation and Transformation - The plan calls for collaborative innovation to promote the transformation of TCM preparations in medical institutions, addressing technological bottlenecks through cooperation among renowned doctors, hospitals, schools, and enterprises [3]. - Modern production lines in TCM facilities are being utilized for the mass production of hospital preparations, indicating a shift towards industrialized TCM [3]. Group 3: Digital and Intelligent Transformation - The plan proposes actions to enhance manufacturing capabilities, including the establishment of 20 smart factories and the cultivation of 10 green factories, alongside the revision of 10 industry standards related to digital technology in TCM [4]. - The application of smart devices in the TCM industry is expected to facilitate the transition from traditional experience-based practices to precision-based methods [4]. - The integration of artificial intelligence and big data is set to create knowledge graphs for classic formulas and experiences from renowned TCM practitioners, enhancing research and resource distribution in the field [4]. Group 4: Future Outlook - The next five years are identified as a critical period for the transformation and upgrading of the TCM industry, with expectations for further modernization and high-quality development as the proposed measures are implemented [5].

Market Overview - The A-share pharmaceutical and biotechnology index rose by 0.14%, outperforming the CSI 300 index by 1.47 percentage points and the ChiNext index by 2.06 percentage points, ranking 15th among 31 sub-industries [4] - The Hong Kong Hang Seng Healthcare Index fell by 1.41%, outperforming the Hang Seng Index by 1.65 percentage points [4] R&D Progress - Heng Rui Medicine submitted an NDA for HRS-9531; He Yu Bio's ABSK043 clinical application is under new undertaking [5] - Xianwei's Enogrelide is in Phase III clinical trials; Xiansheng Pharmaceutical's SIM0278 is in Phase II clinical trials; Yingxi Intelligent's ISM-4808 is in Phase I clinical trials [5] Investment Outlook - Continuous attention to AI healthcare-related investment opportunities is advised [6] - The Ministry of Industry and Information Technology, along with eight other ministries, issued the "Implementation Plan for High-Quality Development of Traditional Chinese Medicine Industry (2026-2030)", aiming to establish a collaborative development system for the entire industry chain by 2030 [6] - The plan focuses on enhancing the stable supply of key traditional Chinese medicine raw materials, improving digital and green levels, and optimizing the structure of the traditional Chinese medicine industry, which is expected to benefit the sector through policy dividends [6] Investment Strategy for 2026 - Future investments in the pharmaceutical sector should increasingly focus on the intrinsic clinical value of medicines, addressing clinical needs of patients [7] - Both domestic medical insurance policies and global expansion strategies are placing higher premiums on clinical value [7]

Group 1: TMT Sector - TMT theme funds experienced significant net value decline, while passive funds increased their positions in TMT theme products. The overall stock market saw fluctuations, with consumer and new energy theme funds performing well, while other theme funds struggled. A total of 24.3 billion yuan flowed out of mid and large-cap theme ETFs, while Hong Kong stock ETFs saw inflows exceeding 10 billion yuan [5]. Group 2: Metals Sector - The prices of non-ferrous metals fell across the board, but gold, tungsten, molybdenum, and vanadium prices increased month-on-month. The financing environment index for small and medium enterprises rose by 6.62% to 50.27 in January. Weekly inventory levels for hot-rolled coils were at a five-year low, while the price of oriented silicon steel hit a new low since 2018 [5][6]. Group 3: Renewable Energy and Environmental Protection - The market remains optimistic about space photovoltaic developments, with a focus on auxiliary materials and equipment. The hydrogen and ammonia sector performed well, with expectations for future carbon policies to enhance green electricity consumption. The dual control of carbon and non-electric applications is anticipated to drive supply optimization [7]. Group 4: Public Utilities - The utilization rates for wind and solar power in 2025 were 94.3% and 94.8%, respectively, both showing year-on-year declines. There is a positive outlook for non-electric applications of renewable energy and direct connections for green electricity, with recommendations to focus on companies like Electric Investment Green Energy and Jinkai New Energy [8]. Group 5: Pharmaceutical Industry - The Ministry of Industry and Information Technology and other departments issued a plan for the high-quality development of traditional Chinese medicine, aiming for a collaborative system by 2030. This policy is expected to raise compliance thresholds and enhance industry concentration, benefiting leading companies with strong integration, quality control, and research capabilities [8]. Group 6: Company Analysis - Yujian Xiaomian - Yujian Xiaomian, a leading chain of Sichuan-Chongqing flavor noodle restaurants, is expanding its national presence through a combination of direct and franchise operations. The company has shown continuous revenue growth and profitability improvements, despite challenges such as high debt and rental costs. The management team is experienced, and operational optimization is expected to further enhance profitability [9].

Core Viewpoint - The implementation plan for the high-quality development of traditional Chinese medicine (TCM) industry aims to establish a collaborative development system by 2030, enhancing the supply capacity of key TCM raw materials and promoting innovation in TCM products [1][2] Group 1: Development Goals - By 2030, the TCM industry is expected to form a collaborative development system across the entire industry chain, with a focus on enhancing the stable supply of key TCM raw materials and improving digital and green levels [1] - The plan includes the cultivation of 60 high-standard TCM raw material production bases and the establishment of five TCM industrial innovation centers [1] Group 2: Innovation and Market Trends - The plan emphasizes the need for continuous innovation in TCM products, aiming to approve a batch of innovative TCM drugs and cultivate 10 major varieties of traditional Chinese medicine [2] - Companies are encouraged to shift from "sales-driven" to "innovation-driven" strategies to enhance their core competitiveness in a market characterized by homogenization [2] Group 3: Research and Development Requirements - TCM companies are required to conduct high-level evidence-based medical research to provide clear efficacy and safety data, targeting unmet medical needs for precise treatment [2] - Establishing a comprehensive digital quality control system from raw materials to finished products is essential for ensuring product reliability [2] Group 4: Digital Transformation - The plan highlights the importance of "digital intelligence" in transforming the TCM industry from traditional practices to modern scientific management [4][5] - Emphasizing digital intelligence aims to standardize and optimize production processes, ensuring consistent product quality and meeting regulatory requirements [6] Group 5: Support for Industry Leaders - The plan proposes actions to cultivate outstanding enterprises in the TCM industry, supporting leading companies in establishing development funds and providing financial services [6] - It encourages the formation of innovation consortia to drive technological advancements and improve the overall modernization level of the TCM industry [6]

Investment Rating - The report upgrades the investment rating for the pharmaceutical and biotechnology industry to "Recommended" [1][42]. Core Insights - The pharmaceutical sector has shown resilience, with a year-to-date return of 3.28%, outperforming the Shanghai Composite Index by 2.99 percentage points [9][23]. - The report highlights the continuous support from policies, particularly for the traditional Chinese medicine (TCM) sector, which is expected to see significant growth due to government initiatives aimed at enhancing the industry [15][17]. - The report emphasizes the importance of innovation in the pharmaceutical sector, noting that domestic companies are gradually improving their innovation capabilities [42]. Summary by Sections Recent Performance - The Shanghai Composite Index fell by 1.33% while the pharmaceutical sector rose by 0.14%, ranking 15th among 31 primary sub-industries [14][23]. - Within the pharmaceutical sub-sectors, traditional Chinese medicine, medical services, and other segments showed varying performance, with traditional Chinese medicine increasing by 2.56% [14][23]. Policy Developments - On February 5, 2026, the Ministry of Industry and Information Technology and other departments released the "Implementation Plan for High-Quality Development of the Traditional Chinese Medicine Industry (2026-2030)," focusing on enhancing the resilience and stability of the TCM supply chain [15][17]. - The plan aims to improve the quality and stable supply of TCM materials and products, which is crucial for the long-term development of the industry [15][17]. Market Dynamics - The report notes that the TCM sector is expected to experience a recovery in performance starting from mid-2025, with improved financial results anticipated in 2026 [9][17]. - The comprehensive index for TCM materials has been declining since July 2024, which is expected to alleviate cost pressures for TCM companies in 2026 [9][17]. Valuation Metrics - As of February 6, 2026, the pharmaceutical sector's valuation stands at 33.3 times PE, with a premium of 32% compared to the overall A-share market (excluding financials) [24]. - The TTM valuation is at 29.4 times PE, below the historical average of 34.9 times PE, indicating potential for growth [24]. Key Companies to Watch - The report suggests focusing on companies such as Aidi Pharmaceutical, Huadong Medicine, Kangnuo Pharmaceutical-B, and others, which are positioned well within the TCM sector and are expected to benefit from policy support and market dynamics [35][43].

Industry Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Outperform the Market" and is maintained [1]. Core Insights - The report highlights the acceleration of policy support for the optimization and transformation of the traditional Chinese medicine (TCM) industry, benefiting leading TCM companies [4][15]. - The report emphasizes the potential benefits for innovative drug companies due to the establishment of a collaborative innovation system and the promotion of new drug approvals [5][15]. - The report notes that the A-share pharmaceutical and biotechnology sector has shown a slight increase of 0.14% in the week from February 2 to February 6, 2026, outperforming the CSI 300 index by 1.47 percentage points [6][18]. Summary by Sections Industry Overview - The closing index for the pharmaceutical and biotechnology sector is 8350.08, with a weekly high of 9323.49 and a low of 6876.88 [1]. Recent Market Performance - The A-share pharmaceutical sector outperformed the CSI 300 index and the ChiNext index during the week, ranking 15th among 31 sub-industries [6][18]. - The TCM sector ranked first among sub-sectors with a weekly increase of 2.56%, while other biopharmaceutical sectors experienced a decline [18]. Policy Developments - The Ministry of Industry and Information Technology and other departments issued a plan for the high-quality development of the TCM industry from 2026 to 2030, aiming to establish a collaborative development system and support leading TCM enterprises [4][15]. - The plan includes fostering a batch of innovative TCM drugs and enhancing the protection of intellectual property for traditional brands [5][16][17]. Investment Recommendations 1. **Innovative Drugs**: The report suggests that innovative drug companies remain a strong investment choice, with a focus on companies with high certainty and low disruption expectations, such as Innovent Biologics and 3SBio [7][21]. 2. **Medical Devices**: The medical device sector is expected to see a recovery in profits, with a focus on companies like Mindray and Kangji Medical, as the impact of centralized procurement diminishes [23][24]. 3. **Traditional Chinese Medicine**: Companies like Yiling Pharmaceutical and Tianjin Zhongxin Pharmaceutical are expected to benefit from policies supporting TCM and the clearing of high inventory levels [28][29][30]. 4. **AI in Healthcare**: Companies involved in AI applications in pharmaceuticals and diagnostics, such as iCarbonX and Huada Gene, are anticipated to benefit from advancements in AI technology [32][34].

Investment Rating - The report indicates a positive outlook for the pharmaceutical industry, particularly highlighting the high-quality development plan for traditional Chinese medicine [2][11]. Core Insights - The pharmaceutical sector's overall performance shows a slight increase, with the Shenwan Pharmaceutical and Biological Index rising by 0.14%, while the Shanghai Composite Index fell by 1.27% [3][2]. - The report emphasizes the implementation of the "High-Quality Development Implementation Plan for Traditional Chinese Medicine Industry (2026-2030)", which aims to enhance the supply chain and technological advancements in the industry [11][12]. - Key performance indicators for major drugs include significant sales growth for Eli Lilly's Tirzepatide, projected to reach $36.5 billion in 2025, and a 54% year-on-year increase in sales for the Alzheimer's drug Lecanemab [14][16]. Market Performance Summary - The Shenwan Pharmaceutical and Biological Index ranked 15th among 31 sub-industries, with various segments showing mixed performance: - Raw materials (+0.6%) - Traditional Chinese medicine (+2.6%) - Chemical preparations (-0.8%) - Blood products (-0.5%) [2][4]. - The overall valuation of the pharmaceutical sector stands at 29.6 times earnings, ranking 13th among 31 primary industries [4][2]. Recent Key Events - The report highlights several significant collaborations and licensing agreements, including: - A $1.5 billion deal between Saint Inbiotech and Genentech for RNAi therapy [17]. - A $1 billion commercialization agreement for a JAKi nasal spray by Jichuan Pharmaceutical [18]. - A $3.88 billion licensing agreement for PD-1 monoclonal antibody H drug by Fuhong Hanlin with Eisai [19] [20]. - The report also notes the IPO preparation of Brain Interface Company, which aims to innovate in neuro-scientific solutions [21]. Investment Recommendations - The report suggests focusing on companies involved in the high-quality development of traditional Chinese medicine, such as Zhaoli Pharmaceutical, Lingrui Pharmaceutical, and Huaren Jiangzhong [2][11]. - It also recommends innovative drug companies and CXO firms, including Hengrui Medicine, BeiGene, and WuXi AppTec, as potential investment opportunities [2][11].

Investment Rating - The report maintains a positive outlook on the pharmaceutical industry, indicating an "Overweight" rating, suggesting that the industry is expected to outperform the overall market [2][33]. Core Insights - The pharmaceutical sector saw a slight increase of 0.14% in the week, while the Shanghai Composite Index decreased by 1.27% [3][2]. - The report highlights the implementation of the "Traditional Chinese Medicine Industry High-Quality Development Implementation Plan (2026-2030)" by the Ministry of Industry and Information Technology and other departments, aiming to enhance the supply chain and technological advancements in the traditional Chinese medicine sector [11][12]. - Key pharmaceutical products such as Eli Lilly's Tirzepatide are projected to generate significant sales, with estimates of $36.5 billion in 2025, reflecting a 99% year-on-year growth for the diabetes version and a 175% growth for the weight loss version [15][17]. - The report notes active licensing and collaboration in the industry, with significant deals such as a $1.5 billion agreement between Saint's RNAi therapy and Genentech, and various other collaborations involving companies like Jichuan Pharmaceutical and Baiyunguan [18][20]. Market Performance Summary - The overall valuation of the pharmaceutical sector is reported at 29.6 times earnings, ranking 13th among 31 sectors [4][14]. - The performance of various sub-sectors includes: - Raw materials (+0.6%) - Traditional Chinese Medicine (+2.6%) - Chemical preparations (-0.8%) - Medical devices (+0.1%) [4][3]. Key Events and Developments - The report emphasizes the importance of the new plan for traditional Chinese medicine, which includes goals such as establishing 60 high-standard raw material production bases and developing 10 major traditional Chinese medicine products by 2030 [12][11]. - Notable company developments include: - Eli Lilly's projected revenue growth driven by Tirzepatide [15]. - And the announcement of significant profit forecasts from Heptares Pharmaceuticals, indicating a shift towards profitability [16]. Investment Recommendations - The report suggests focusing on domestic companies related to traditional Chinese medicine, such as Zoli Pharmaceutical and Yunnan Baiyao, as well as innovative drug companies like Heng Rui Pharmaceutical and Bai Jie Shen Zhou [2][18].

Group 1 - The Chinese medicine sector experienced a short-term surge, with Hansen Pharmaceutical achieving two consecutive trading limits, and companies such as Guhang Medicine, China Resources Sanjiu, Guangdong Wannianqing, Biotech Valley, and Dong'e Ejiao also seeing gains [1] - The Chinese Medicine ETF (560080) recorded a transaction volume of 78.1084 million yuan [1] - The recent rise in the sector was influenced by the "Implementation Plan for the High-Quality Development of the Traditional Chinese Medicine Industry (2026-2030)" [1]